<DOC>
	<DOC>NCT00677924</DOC>
	<brief_summary>The purpose of this trial is to determine the safety and efficacy of Zalutumumab alone or in combination with Irinotecan for the treatment of patients with Colorectal Cancer</brief_summary>
	<brief_title>Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Males and Females age â‰¥ 18 years 2. Confirmed diagnosis of CRC 3. Documented disease progression 4. Failure and/or intolerance to standard chemotherapy 1. Prior treatment with antiEGFR antibodies other than cetuximab 2. Expected survival &lt; 3 months 3. Clinical significant cardiac disease and/or uncontrolled medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Colorectal Tumors</keyword>
	<keyword>Colorectal Carcinoma</keyword>
</DOC>